| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
At Mayo Clinic, we know the importance of laboratory testing in a patient's episode of care. Our unique combination of specialized laboratories and hematology patient care clinics gives us the ability to put into practice clinically proven, cost-effective, patient care-driven testing approaches for hundreds of hematologic conditions. In addition to the latest testing, when you partner with us, you extend your network to include some of the world's leading hematology experts.
Visit us at booth #2927 at ASH 2018 to discuss how our testing can integrate with your practice.
View our Key Happenings at ASH 2018.
View our in-booth "Ask the Expert" sessions.
Now available at Mayo Clinic, monoclonal-protein (M-protein) detection by matrix-assisted layer desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) provides a more sensitive and specific result than traditional immunofixation methodologies, which have been in use for more than 45 years. This new methodology is available with the following tests:
The Mayo Clinic Molecular Hematology Laboratory provides accurate results and interpretations with an emphasis on genes of clinical significance for your patients.
Key advantages of the Mayo Clinic NGS testing include:
Disease-specific panels that offer a high depth of coverage with relevant genetics targets for optimal tumor characterization.
Panels of varying sizes that fit patient clinical needs.
A comprehensive review of results by a board-certified hematopathologist.
Mayo Clinic’s comprehensive multiple myeloma assessments add valuable information throughout patients’ medical journeys and support various health care providers with their continued treatment of multiple myeloma patients.
Screening: SMOGA assesses monoclonal proteins for progression risks of plasma cell proliferative disorders from undetermined significant monoclonal gammopathy. The analysis includes a free light chains array for high diagnostic sensitivity to disorders that often do not have serum monoclonal proteins in high enough concentrations for detection or quantification. M-protein detection is performed by new MALDI-TOF MS methodologies.
Diagnosis: MSMRT is useful for measuring the risk stratification of patients with newly diagnosed multiple myeloma and determining treatment and management decisions. The interpretive MSMRT report classifies patients into either standard or high-risk categories based on the results of two assays: flow cytometry using specific plasma cell markers and, when appropriate, fluorescence in situ hybridization (FISH) for specific multiple myeloma-associated abnormalities.
Monitoring: The protein electrophoresis and monoclonal gammopathy tests recently received updates with the new mass spectrometry (MS) approach, which identifies M-proteins using high-resolution molecular-mass measurements that achieve superior sensitivity compared to traditional methods. When appropriate, M-protein detection is performed by new MALDI-TOF MS methodologies.
Minimal Residual Disease (MRD): The MRDMM test delivers valuable prognostic information to health care providers by assessing the level of MRD after therapy completion. The MRD level can also support decisions for continued treatment of multiple myeloma patients. The greater depth of response can lead to a longer time of progression and overall survival.
Consultative Test Panels for Complex or Difficult Diagnostic Problems
Our consultative test panels guide ordering patterns to address specific clinical questions, eliminate false-positive results, and reduce unnecessary testing. For health care providers requesting a single test, many components of these evaluations can be ordered individually.
Aids in the diagnosis of hemophilia A using a 2-stage assay, especially when the 1-stage assay was normal, as there is a subset of mild hemophilia A patients who have shown discrepantly low results when measured with the 2-stage (chromogenic) assay.
With new treatment options using long-acting glycoPEGylated products, this testing is useful for monitoring patients receiving coagulation factor replacement therapy of selected extended half-life coagulation factor replacements.
Aids in the diagnosis of hemophilia A using a 2-stage assay, especially when the 1-stage assay was normal, as there is a subset of mild hemophilia A patients who have shown discrepantly low results when measured with the 2-stage (chromogenic) assay.
With treatment options using long-acting glycoPEGylated products, this test is useful for monitoring patients receiving coagulation factor replacement therapy of selected extended half-life coagulation factor replacements. Optimal laboratory monitoring of selected extended half-life factor IX replacement therapy (e.g., glycoPEGylated factor FIX) may be achieved with the chromogenic factor IX assay. Elevated factor IX levels may be associated with acute or chronic inflammation, excess factor IX replacement therapy or, rarely, as a result of rare genetic mutation factor IX Padua.
Our Mayo Clinic colleagues are in San Diego for the 60th American Society of Hematology Annual Meeting & Exhibition. Follow this blog for live updates from #ASH18 as we attend the conference, mingle with colleagues at booth #2927, and have a little fun.
